Immunogenicity of Ad26.COV2.S vaccine for COVID-19


What The Study Did:

In this phase 1 study, a single immunization with Ad26.COV2.S (Janssen/Johnson & Johnson) vaccine induced rapid binding and neutralization antibody responses as well as cellular immune responses. Two phase 3 clinical trials are currently underway to determine the efficacy of the Ad26.COV2.S vaccine.


Authors:

Dan H. Barouch, M.D., Ph.D., of Beth Israel Deaconess Medical Center in Boston, is the corresponding author.


To access the embargoed study:

Visit our For The Media website at this link

https:/

/

media.

jamanetwork.

com/

(doi:10.1001/jama.2021.3645)


Editor’s Note:

Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

###


Media advisory:

The full article is linked to this news release.


Embed this link to provide your readers free access to the full-text article

This link will be live at the embargo time

https:/

/

jamanetwork.

com/

journals/

jama/

fullarticle/

10.

1001/

jama.

2021.

3645?guestAccessKey=

1d3b0702-ad7c-4150-85fc-c526b5290ac0&utm_source=

For_The_Media&utm_medium=

referral&utm_campaign=

ftm_links&utm_content=

tfl&utm_term=

031121

This part of information is sourced from https://www.eurekalert.org/pub_releases/2021-03/jn-ioa031121.php

withyou android app